is this you? Claim your profile.
is this you? Claim your profile.
+ Get 10 Free Contacts a Month
It's free and takes 30 seconds
Sarah Terry, MPH
Managing Director Ms. Terry is global Managing Director of Life Science Analytics, a biomedical database company owned by Datamonitor, where she oversees product development and sales, develops corporate partnerships, and speaks at industry events. Before moving into her role at Life Science Analytics, she managed North American Healthcare and Financial Markets operations for Datamonitor as Senior Vice President. Sarah also sits on Datamonitor's EMC. Ms. Terry's areas of expertise include pharmaceutical market valuation and forecasting, epidemiology, target identification, product prioritization and portfolio management. Prior to Datamonitor, she worked at Harte-Hanks, Visiting Nurse Service of New York, and the New York City Department of Health. She holds a Masters in Public Health in Epidemiology from the Mailman School of Public Health, Columbia University and a Bachelor of Science in Biology and Community Health from Tufts University.
ePT--the Electronic Newsletter of Pharmaceutical Technology, Sep 28, 2006 - PharmTech
Strong growth is projected for cytotoxics through 2009, but the market then will see generic drug erosion, according to Sarah Terry Johnston, vice-president, healthcare, Datamonitor PLC.
MedTRACK capabilities highlighted on Inside Business TV program
In a recent interview, Sarah Terry, President of Life Science Analytics, Inc. discussed the current state of the pharmaceutical and biotech industry with Inside Business.
In this television interview Ms. Terry outlines what it takes to be successful in this ever changing market by using MedTRACK. She discusses how MedTRACK allows subscribers to reduce costs, manage portfolios, and find unmet needs by utilizing its comprehensive listing of companies, products, and deals. Finally, Ms. Terry explains how MedTRACK helps bring together collaborators to bring drugs to the market faster and less expensively. Click here to see the video Sarah Terry, President - Life Science Analytics
"Genzyme is strongly positioned in a number of niche markets, which are very lucrative despite low patient numbers," said Sarah Terry, president, global managing director, Life Science Analytics, a Datamonitor company.
"Furthermore, a number of key brands in its portfolio have been granted orphan drug status thereby providing a period of market exclusivity-7 years in the United States and 10 years in the European Union." Drugs that are currently in Genzyme's rare disease pipeline include Genz-112638 oral therapy for Gaucher disease; Ataluren for Duchenne and Becker muscular dystrophy; Acid Sphingomyelinase for Neimann-Pick Type B; gene therapy for Parkinson's disease; and Neo-GAA for next-generation Pompe disease treatment. Last May, Genzyme won FDA approval for alglucosidase alfa (Lumizyme), for the treatment of late-onset Pompe disease. "Cerezyme [for treatment of Gaucher disease], Fabrazyme [for Fabry disease], and Myozyme/Lumizyme [for Pompe disease] are the key growth drivers-all for rare genetic disorders," Terry said. "Specialty and niche markets are areas of high unmet need with little to no competition, and with orphan status, longer periods of exclusivity," said Terry. "All of these mean greater growth prospects for pharma whose growth has been stalled by patent expiries and generic incursion." Biologics are one of the top growth areas, experiencing growth of 8% to 10% per year, according to Terry. In 2002, small molecules comprised 91% of pharmaceutical sales, in 2014 they will only account for 71% while biologics will have grown to 22%. Merger and acquisition activity remains at very high levels in the pharmaceutical and biotech industry, agreed Berger. "The last few years have seen a record amount of biopharma M&A activity, and [this] transaction suggests that trend continues." This acquisition also means other things, according to Terry. "Based on some of the manufacturing issues Genzyme has faced in the past, providers can have greater confidence in the safety and sourcing of their products and the reputation and standards that Sanofi-aventis brings to the table," she said. "And, with the financial backing of Sanofi-aventis, faster development of products is possible, or, more simply, bringing products to the market faster to the patients who need them the most." The fallout from Genzyme's manufacturing issues-lowering the company's share price-coupled with an impressive sales growth projection, has made Genzyme a prime acquisition target and could make it the largest buyout since Roche's acquisition of Genentech, added Terry.
MedTRACK in the News
Life Science Analytics' President, Sarah Terry, Presents at Two Meetings
Sarah Terry is presenting the State of the Industry Keynote Address on Sunday, July 11th. Interview with Sarah Terry, President of LSA, Inc. Sarah Terry, President of Life Science Analytics, Inc. discussed the current state of the pharmaceutical and biotech industry with Inside Business The PhramaChem Outlook 2009 report was presented by Sarah Terry at DCAT week in New York City. Sarah Terry, President of LSA to discuss Pharma Growth Prospects and Key Trends at DCAT Discuss current market trends and strategies for future success at DCAT's 2009 PharmaChem Outlook, presented by Sarah Terry, President of Life Science Analytics, Inc.